The current status of time dependent CYP inhibition assay and in silico drug-drug interaction predictions

Current Topics in Medicinal Chemistry

Volumn 12, Issue 11, 2012, Pages 1291-1297

  Yan, Zhengyin ^a   Caldwell, Gary W ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Drug drug interactions; Time dependent CYP inhibition

Indexed keywords

CYTOCHROME P450; MICROSOME ENZYME; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ALGORITHM; AREA UNDER THE CURVE; ASSAY; CATALYSIS; COMPUTER MODEL; DRUG DESIGN; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; FLUORESCENCE; HUMAN; KINETICS; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; MATHEMATICAL MODEL; NONHUMAN; PREDICTION; PROTEIN DEGRADATION; REVIEW; SCREENING; TIME; TIME DEPENDENT INHIBITION;

EID: 84861740169     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612800672871     Document Type: Review

References (41)

1. Kohler, G.I.; Bode-Boger, S.M.; Busse, R.; Hoopmann, M.; Welte T; Boger, R.H. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Intern. J. of Clin. Pharma. Therap. 2000, 38(11), 504-13.
2. Kalgutkar, A.S.; Obach, R. S.; Maurer, T.S. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drugdrug interactions and idiosyncratic adverse drug reactions. Curr. Drug Metab. 2007, 8(5), 407-447.
3. Perloff, E. S; Mason, A. K; Dehal, S. S; Blanchard, A. P; Morgan, L.; Ho, T.; Dandeneau, A.; Crocker, R.M.; Chandler, C.M.; Boily, N.; Crespi, C.L.; Stresser, D. M. Validation of cytochrome P450 timedependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica 2009, 39(2), 99-112.
4. Riley, R. J.; Grime, K.; Weaver, R. Time-dependent CYP inhibition. Expert Opin. Drug Metab. & Toxicol. 2007, 3(1), 51-66.
5. Yan, Z.; Caldwell, G. W. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr. Top. Med. Chem. 2001, 1(5), 403-425.
6. Hollenberg, P.F. Characteristics and common properties of inhibitors, inducers, and activators of CYP [cytochrome P 450] enzymes. Drug Metab. Rev. 2002, 34(1 & 2), 17-35.
7. Caldwell, G.W., Yan, Z. Screening for reactive intermediates and toxicity assessment in drug discovery Curr. Opin. Drug Disc. Develop. 2006, 9, 47-60.
8. Yan, Z.; Rafferty, B.; Caldwell, G.W.; Masucci, J. A. Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses. Europ. J. Drug Metab. Pharmacok. 2002, 27(4), 281-287.
9. Naritomi, Y.; Teramura, Y.; Terashita, Shigeyuki; Kagayama, Akira. Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors. Drug Metab. Pharmacok. 2004, 19(1), 55-61.
10. Ghanbari, F.; Rowland-Yeo, K.; Bloomer, J. C.; Clarke, S. E.; Lennard, M. S.; Tucker, G. T.; Rostami-Hodjegan, A. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr. Drug Metab. 2006, 7(3), 315-334.
11. Lim, H-K; Duczak, N. Jr.; Brougham, L.; Elliot, M.; Patel, K.; Chan, K. Automated screening with confirmation of mechanismbased inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab. Dispos. 2005, 33(8), 1211-1219.
12. Mori, K.; Hashimoto, H.; Takatsu, H.; Tsuda-Tsukimoto, M.; Kume, T. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development. Xenobiotica 2009, 39(6), 415-422.
13. Berry, L.M.; Zhao, Z. An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. Drug Metab. Lett. 2008, 2(1), 51-59.
14. Dasgupta, M.; Tang, W.; Caldwell, G.W.; Yan, Z. Use of stable isotope labeled probes to facilitate liquid chromatography/mass spectrometry based high-throughput screening of time-dependent CYP inhibitors. Rapid Comm. Mass Spectr. 2010, 24(15), 2177-2185.
15. Silverman, R. B. Mechanism-based enzyme inactivators. Methods in Enzymology 1995, 249 (Enzyme Kinetics and Mechanism, Part D), 240-283.
16. Grimm, S.W.; Einolf, H.J.; Hall, S.D.; He, K.; Lim, H-K; Ling, K.-H. J.; Lu, C.; Nomeir, A. A.; Seibert, E.; Skordos, K.W.; Tonn, G. R.; Van Horn, R.; Wang, R.W.; Wong, Y. N.; Yang, T. J.; Obach, R. S. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the Pharmaceutical Research and Manufacturers of America. Drug Metab. Dispos. 2009, 37(7), 1355-1370
17. Mayhew, B.S.; Jones, D.R.; Hall, S.D. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos. 2000, 28(9), 1031-1037.
18. Shardlow, C.E.; Generaux, G.T.; MacLauchlin, C.C.; Pons, N.; Skordos, K.W.; Bloomer, J.C. Utilizing drug-drug interaction prediction tools during drug development: enhanced decision making based on clinical risk. Drug Metab. Dispos. 2011, 39(11), 2076-2084.
19. Wong, S. G. Prediction of drug-drug interactions arising from mechanism-based inactivation: key input parameters and impact on risk assessment. Curr. Drug Metab. 2011, 12(9), 871-890.
20. Wienkers, L.C.; Heath, T. G. Predicting in vivo drug interactions from in vitro drug discovery data. Nature Reviews Drug Disc. 2005, 4(10), 825-833.
21. Obach, R. S.; Walsky, R. L.; Venkatakrishnan, K.; Gaman, E. A.; Houston, J. B.; Tremaine, L. M. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharm. Experim. Therap. 2006, 316(1), 336-348.
22. Obach, R. S.; Walsky, R. L.; Venkatakrishnan, K. Mechanismbased inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 2007, 35(2), 246-255.
23. Galetin, A.; Gertz, M.; Houston, J. B. Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opinion on Drug Metab. & Toxicol. 2008, 4(7), 909-922.
24. Yeo, K. R.; Walsky, R.L.; Jamei, M.; Rostami-Hodjegan, A.; Tucker, G. T. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover. Europ. J. Pharma. Sci. 2011, 43(3), 160-173.
25. Jamei, M.; Marciniak, S.; Feng, K.; Barnett, A.; Tucker, G.; Rostami-Hodjegan, A. The Simcyp population-based ADME simulator. Expert Opinion Drug Metab. & Toxicol. 2009, 5(2), 211-223.
26. Wang, Y-H. Confidence assessment of the simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors. Drug Metab. Dispos. 2010, 38(7),1094-1104.
27. Einolf, H. J. Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 2007, 37(10/11), 1257-1294.
28. Yang, J.; Jamei, M.; Yeo, K. R.; Tucker, G.T.; Rostami-Hodjegan, A. Kinetic values for mechanism-based enzyme inhibition: Assessing the bias introduced by the conventional experimental protocol. Europ. J. Pharma. Sci. 2005, 26(3-4), 334-340.
29. Van, L.M.; Heydari, A.; Yang, J.; Hargreaves, J.; Yeo, K. R.K.; Lennard, M.S.; Tucker, G.T.; Rostami-Hodjegan, A. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy). J. Psychopharma. 2006, 20(6), 834-841.
30. Parkinson, A.; Kazmi, F.; Buckley, D. B.; Yerino, P.; Paris, B. L.; Holsapple, J.; Toren, P.; Otradovec, S.M.; Ogilvie, B. W. An evaluation of the dilution method for identifying metabolismdependent inhibitors of cytochrome P450 enzymes. Drug Metab. Dispos. 2011, 39(8), 1370-1387.
31. Tran, T.H.; Von Moltke, L. L.; Venkatakrishnan, K.; Granda, B.W.; Gibbs, M.A.; Obach, R. S.; Harmatz, J.S.; Greenblatt, D.J. Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab. Dispos. 2002, 30(12), 1441-1445.
32. Kumar, V.; Wahlstrom, J.L.; Rock, D.A.; Warren, C.J.; Gorman, L.A.; Tracy, T.S. CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab. Dispos. 2006, 34(12), 1966-1975.
33. Ghanbari, F.; Rowland-Yeo, K.; Bloomer, J. C.; Clarke, S. E.; Lennard, M. S.; Tucker, G. T.; Rostami-Hodjegan, A. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr. Drug Metab. 2006, 7(3), 315-334.
34. Venkatakrishnan, K.; Obach, R. S. Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr. Drug Metab. 2007, 8(5), 449-462.
35. Brown, H.S.; Chadwick, A.; Houston, J.B. Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination. Drug Metab. Dispos. 2007, 35(11), 2119-2126.
36. Chen, Y.; Liu, L.; Monshouwer, M.; Fretland, A.J. Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions. Drug Metab. Dispos. 2011, 39(11), 2085-2092.
37. Xu, L.; Chen, Y.; Pan, Y.; Skiles, G.L.; Shou, M. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator. Drug Metab. Dispos. 2009, 37(12), 2330-2339.
38. Gorski, J.C.; Jones, D.R.; Haehner-Daniels, B.D.; Hamman, M.A.; O'Mara, E.M.; Hall, S.D. The contribution of intestinal and hepatic CYP 3A to the interaction between midazolam and clarithromycin. Clin. Pharma. Therap. (St. Louis), 1998, 64(2), 133-143.
39. Yang, J.; Liao, M.; Shou, M.; Jamei, M.; Yeo, K. R.; Tucker, G.T.; Rostami-Hodjegan, A. Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr. Drug Metab. 2008, 9(5), 384-393.
40. Mousa, O.; Brater, D. C.; Sundblad, K. J.; Hall, S. D. The interaction of diltiazem with simvastatin. Clin. Pharma. Therap. (St. Louis), 2000, 67(3), 267-274.
41. Fontana, E.; Dansette, P. M.; Poli, S. M. Cytochrome P 450 enzymes mechanism based inhibitors: Common sub-structures and reactivity. Curr. Drug Metab. 2005, 6(5), 413-454.